Effectiveness of immune checkpoint inhibitors in the treatment of kidney cancer oral metastasis. A case report.

Fiche publication

Date publication

mai 2024

Journal

Journal of stomatology, oral and maxillofacial surgery

Auteurs

Membres identifiés du Cancéropôle Est :
Dr BOULAGNON-ROMBI Camille

Tous les auteurs :
Bruckmann M, Brenet E, Boulagnon-Rombi C, Louvrier A, Mauprivez C

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/38719194

Résumé

Oral cavity metastasis from renal cell carcinoma is rare with poor prognosis. Recently immune checkpoint inhibitors (ICIs) have shown promising outcomes in the treatment of advanced RCC. Herein, we report a case of palatal lesion mimicking vascular tumor in a 60-year-old woman with locally advanced kidney cancer (T3aN0M0). She underwent an excisional biopsy, and histopathological examinations revealed an oral metastasis from clear cell renal cell carcinoma (ccRCC). The patient was treated with a combination of two ICIs with nivolumab, a programmed death 1 (PD-1), and ipilimumab, a cytotoxic T-lymphocyte-associated antigen 4 (CTLA4). After 3 cycles of systemic immunotherapy, the palate was completely well healed and after 13 months of follow-up, there was no evidence of recurrence. Regarding treatments, radical surgery is often recommended due to a high local control in case of solitary lesions or oligo-metastases. However, this option therapy is associated with a poor quality of life. To the best of our knowledge, this is the first case to suggest the benefits of ICIs in the treatment of oral metastases from ccRCC. Combining ICIs with conservative surgery could be another treatment option for oral metastasis in patients with renal cell carcinoma.